Welcome! It's on Saturday 26th July 2014


  • CAPS babies can now be treated at home

    A first of its kind treatment for babies as young as eight months who have cryopyrin-associated periodic syndromes (CAPS) has just been licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA) for use in the UK.

  • Humira recommended in Wales

    The All Wales Medicines Strategy Group has recommended AbbVie’s Humira (adalimumab) as an option for use in NHS Wales.

  • EU gives Celgene go-ahead for Revlimid

    The European Commission has granted approval to Revlimid (lenalidomide) for the treatment of patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are failing.